ACH-1625 has demonstrated clinical proof-of-concept as a potent inhibitor of HCV NS3 protease, with good safety, tolerability, a unique PK profile, and potential for once-daily dosing.

ACH-1095 is a novel-mechanism NS4A antagonist currently being prepared for IND filing.

ACH-2684 is a high-potency protease inhibitor with potency in the picomolar range, and activity against all HCV genotypes, including highly resistant strains of the HCV virus.

ACH-2928, an NS5A inhibitor with potent activity against all genotypes, is highly effective in combination with NS3 protease inhibitors, NS5B polymerase inhibitors, interferon and ribavirin.

ACH-702 is a broad-spectrum bactericidal compound with a novel target profile against three bacterial DNA replication enzymes.

ELVUCITABINE is a nucleoside with demonstrated potent activity against both HBV and HIV, including against HIV strains resistant to other NRTIs.